New drug combo may replace harsh transplant for hodgkin lymphoma patients

NCT ID NCT05502250

Ongoing Disease control Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called tislelizumab combined with chemotherapy for people whose Hodgkin lymphoma has returned or not responded to initial treatment. The goal is to see if this approach works as well as the standard intensive chemotherapy and stem cell transplant. About 75 adults with confirmed Hodgkin lymphoma will receive the drug combo, and those who achieve complete remission will continue on tislelizumab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic Hodgkin lymphoma Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HODGKIN LYMPHOMA

Contacts and locations

Locations

BE-Bruxelles-STLUC

Brussels, Belgium
DK-Aarhus N-AUH

Aarhus, Denmark
DK-Copenhagen-RIGSHOSPITALET

Copenhagen, Denmark
DK-Odense-OUH

Odense, Denmark
NL-Amersfoort-MEANDERMC

Amersfoort, Netherlands
NL-Amsterdam-AMC

Amsterdam, Netherlands
NL-Arnhem-RIJNSTATE

Arnhem, Netherlands
NL-Den Haag-HAGA

The Hague, Netherlands
NL-Eindhoven-MAXIMAMC

Eindhoven, Netherlands
NL-Goes-ADRZ

Goes, Netherlands
NL-Groningen-UMCG

Groningen, Netherlands
NL-Hoofddorp-SPAARNEGASTHUIS

Hoofddorp, Netherlands
NL-Leeuwarden-MCL

Leeuwarden, Netherlands
NL-Maastricht-MUMC

Maastricht, Netherlands
NL-Rotterdam-ERASMUSMC

Rotterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.